The global cell analysis market size reached US$ 20.7 Billion in 2023. Looking forward, the publisher expects the market to reach US$ 40.1 Billion by 2032, exhibiting a growth rate (CAGR) of 7.62% during 2023-2032. The shift towards personalized medicine, increasing cases of cancer across the globe, and growing integration of artificial intelligence and machine learning in cell analysis are some of the key factors, catalyzing the growth of the market.
The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer cell analysis. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.
For instance, according to the data published by the Congressional Budget Office, in 2021, it was observed that pharmaceutical industries spent nearly US$ 200 Billion on research and development in 2020 globally, compared to US$ 83 Million in 2019. Similarly, Danaher Corporation invested US$ 1.74 billion in its research and development in 2021, as compared to US$ 1.34 billion in 2020. In addition, Bio-Rad Laboratories Inc., invested US$ 879.6 Million in 2021 as compared to US$ 800.3 Million in 2020. Thus, the rising investment in research and development by the companies further increases the capabilities of the company to adopt innovative cell analysis techniques, thereby propelling the cell analysis market growth.
Similarly, in November 2022, Sony Corporation launched the SFA - Life Sciences Cloud Platform, a flow cytometry data analysis cloud solution that can quickly identify rare cells, such as cancer cells and stem cells, from a wide variety of cell populations, using data obtained from flow cytometers. In addition to this, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that is intended to enable the development of cell therapies. Such innovations are expected to bolster the cell analysis market demand in the coming years.
Flow cytometry products are pivotal in the cell analysis market, offering precise quantification and characterization of cells based on their physical and chemical properties. Key components include flow cytometers, which analyze cells in fluid suspension using lasers to detect fluorescently labeled cells. Reagents such as fluorescent dyes and antibodies enable specific labeling for biomarker detection, while software facilitates data analysis and visualization. These products are essential in research, clinical diagnostics, and drug discovery, providing insights into cell function, differentiation, and disease mechanisms. Ongoing advancements in technology are enhancing sensitivity, multiplexing capabilities, and automation, expanding the utility of flow cytometry in diverse biomedical applications.
Cell identification in cell analysis involves various techniques to distinguish and classify cells based on their morphological, molecular, or functional characteristics. Methods include microscopy for visual inspection, flow cytometry for quantitative analysis of cell surface markers, and molecular techniques like PCR for genetic profiling. Immunohistochemistry and immunofluorescence enable detection of specific proteins within tissues or cell samples. Advances in single-cell analysis technologies allow for high-resolution characterization of individual cells within heterogeneous populations. Accurate cell identification is crucial in understanding disease mechanisms, assessing treatment responses, and advancing personalized medicine by tailoring therapies based on individual cell profiles.
Molecular approaches in cell analysis focus on studying cellular components at the molecular level to understand biological processes and diseases. Techniques include PCR (Polymerase Chain Reaction) for amplifying and detecting DNA or RNA sequences, Western blotting for protein detection and quantification, and next-generation sequencing (NGS) for comprehensive genomic analysis.
These methods enable researchers to investigate gene expression, mutations, protein interactions, and epigenetic modifications within cells. Molecular approaches are vital in biomarker discovery, drug development, and personalized medicine, offering insights into cellular function and disease mechanisms with high sensitivity and specificity. Continued advancements enhance their utility in diverse biomedical research applications.
Pharmaceutical and biotechnology companies develop and commercialize drugs and therapies for medical use. They conduct extensive research and clinical trials to discover new compounds, validate their efficacy and safety, and obtain regulatory approvals. Contract Research Organizations (CROs) support these efforts by providing specialized, such as clinical trial management, data analysis, and regulatory compliance. CROs enable companies to outsource non-core activities, accelerate timelines, and manage costs effectively. Furthermore, the increasing rate of new drug development is also contributing to the segment’s growth. For instance, between 2010 and 2019, around 38 new drugs were approved each year, on an average.
That is about a 60% increase compared with the previous decade. Drug approvals reached a new peak in 2018, surpassing the record number of approvals of the late 1990s. The cell analysis market statistics by the publisher indicate that together, pharmaceutical/biotech firms and CROs are playing crucial roles in advancing healthcare innovation, bringing new treatments to market, and improving patient outcomes through rigorous scientific research and development.
The growth of the region can be attributed to the increase in incidences of cancer and rising corporate and government funding in cell-based research. For instance, according to the Canadian Cancer Statistics 2022 Special Report, the number of people living with and after cancer in Canada continued to grow to over 1.5 million people. Additionally, according to another report, 2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. Approximately 1 in 4 Canadians is expected to die of the disease. Besides this, the presence of major companies, the growing number of product launches, and the strong R&D in biotechnology are further positively impacting the cell analysis market outlook.
For instance, in September 2022, Becton, Dickinson, and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher-quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.
2. What is the expected growth rate of the global cell analysis market during 2024-2032?
3. What are the key factors driving the global cell analysis market?
4. What has been the impact of COVID-19 on the global cell analysis market?
5. What is the breakup of the global cell analysis market based on the product?
6. What is the breakup of the global cell analysis market based on the analysis type?
7. What is the breakup of the global cell analysis market based on the techniques?
8. What is the breakup of the global cell analysis market based on the end-user?
9. What are the key regions in the global cell analysis market?
10. Who are the key players/companies in the global cell analysis market?
Cell Analysis Market Analysis:
- Major Market Drivers: Increasing demand for cell analysis tools in drug discovery and development, particularly in fields like oncology and immunology, is primarily driving the market growth. The rising prevalence of chronic diseases like cancer and autoimmune disorders is augmenting the need for advanced cell analysis techniques for disease diagnosis and treatment, which is also contributing to the market growth.
- Key Market Trends: The expansion of regenerative medicine and stem cell research is augmenting the need for cell analysis tools to study cell behavior, differentiation, and therapeutic applications, which is creating a positive outlook for the overall market.
- Competitive Landscape: Some of the leading cell analysis companies operating in the global market include Agilent Technologies Inc., BD Biosciences, Bio-RAD Laboratories Inc., Danaher Corporation, Illumina Inc., Merck KGaA, Miltenyi Biotec, Olympus Corporation, PerkinElmer Inc., Promega Corporation, Sysmex Corporation, and Thermo Fisher Scientific, among others.
- Geographical Trends: According to the report, North America currently dominates the global market. The growth of the region can be attributed to the increase in incidences of cancer and rising corporate and government funding in cell-based research activities.
- Challenges and Opportunities: Challenges include the complexity of interpreting large-scale data, maintaining cell viability during analysis, and the high cost of advanced technologies. Opportunities lie in expanding applications in personalized medicines, regenerative therapies, and the integration of artificial intelligence to enhance analytical capabilities and streamline processes.
Global Cell Analysis Market Trends:
Growing Burden of Cancer
The rising number of cancer cases across the world is primarily driving the market growth. Cell analysis tools and techniques in cancer research enable precise characterization of tumor cells, including their genetic mutations, protein expression profiles, and cellular interactions within the tumor microenvironment. The growing number of cancer patients is catalyzing the cell analysis market share. For instance, as per an American Cancer Society 2022 update, around 1,918,030 new cancer cases were estimated in the U.S. in 2022. Furthermore, lung cancer and breast cancer are two of the most common cancers found among individuals.The Canadian Cancer Society (CCS) stated that in 2020, nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. About 21,200 Canadians were expected to die from lung cancer, which represented 25% of all cancer deaths in 2020. This indicates an inflating need for effective and more advanced cancer cell analysis. Thus, the increasing demand for effective and lasting cancer treatment is anticipated to offer lucrative growth opportunities to the overall market.
Increasing Development of Novel Molecules
The rising prevalence of various infectious diseases is prompting the development of novel molecules and vaccines, which in turn is augmenting the cell analysis market revenue. Cell analysis tools play a crucial role in drug discovery and development by enabling researchers to assess the efficacy, safety, and mechanism of action of potential drug candidates. Furthermore, various pharmaceutical and biotech firms are increasingly relying on cell analysis techniques and tools to introduce new and improved drugs.For instance, according to the data published by the Congressional Budget Office, in 2021, it was observed that pharmaceutical industries spent nearly US$ 200 Billion on research and development in 2020 globally, compared to US$ 83 Million in 2019. Similarly, Danaher Corporation invested US$ 1.74 billion in its research and development in 2021, as compared to US$ 1.34 billion in 2020. In addition, Bio-Rad Laboratories Inc., invested US$ 879.6 Million in 2021 as compared to US$ 800.3 Million in 2020. Thus, the rising investment in research and development by the companies further increases the capabilities of the company to adopt innovative cell analysis techniques, thereby propelling the cell analysis market growth.
Rising Number of Strategic Collaborations and Acquisitions
Various key market players are forming partnerships and collaborations to develop new and improved cell analysis methods, tools, and techniques. For instance, in August 2022, DeNovix Inc., the manufacturer of the award-winning CellDrop Automated Cell Counter, developed two dedicated nuclei counting apps capable of differentiating isolated nuclei and intact cells from debris. The CellDrop Series is a line of image-based, automated cell counters. Systems include a high-definition 7-inch touchscreen for live preview and instant review of results.Similarly, in November 2022, Sony Corporation launched the SFA - Life Sciences Cloud Platform, a flow cytometry data analysis cloud solution that can quickly identify rare cells, such as cancer cells and stem cells, from a wide variety of cell populations, using data obtained from flow cytometers. In addition to this, in March 2022, Thermo Fisher Scientific introduced a new large-volume electroporation system that is intended to enable the development of cell therapies. Such innovations are expected to bolster the cell analysis market demand in the coming years.
Global Cell Analysis Industry Segmentation:
The publisher provides an analysis of the key trends in each segment of the global cell analysis market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product, analysis type, techniques, and end-user.Breakup by Product:
- Flow Cytometry Products
- qPCR Products
- Cell Microarrays
- Microscopes
- Spectrophotometers
- Cell Counters
- HCS Systems
- Others
Flow cytometry products exhibit a clear dominance in the market
Flow cytometry products are pivotal in the cell analysis market, offering precise quantification and characterization of cells based on their physical and chemical properties. Key components include flow cytometers, which analyze cells in fluid suspension using lasers to detect fluorescently labeled cells. Reagents such as fluorescent dyes and antibodies enable specific labeling for biomarker detection, while software facilitates data analysis and visualization. These products are essential in research, clinical diagnostics, and drug discovery, providing insights into cell function, differentiation, and disease mechanisms. Ongoing advancements in technology are enhancing sensitivity, multiplexing capabilities, and automation, expanding the utility of flow cytometry in diverse biomedical applications.
Breakup by Analysis Type:
- Cell Identification
- Cell Viability
- Cell Signaling Pathways/Signal Transduction
- Cell Proliferation
- Cell Counting and Quality Control
- Cell Interaction
- Target Identification and Validation
- Single-Cell Analysis
- Others
Cell identification analysis type holds the majority of the total market share
Cell identification in cell analysis involves various techniques to distinguish and classify cells based on their morphological, molecular, or functional characteristics. Methods include microscopy for visual inspection, flow cytometry for quantitative analysis of cell surface markers, and molecular techniques like PCR for genetic profiling. Immunohistochemistry and immunofluorescence enable detection of specific proteins within tissues or cell samples. Advances in single-cell analysis technologies allow for high-resolution characterization of individual cells within heterogeneous populations. Accurate cell identification is crucial in understanding disease mechanisms, assessing treatment responses, and advancing personalized medicine by tailoring therapies based on individual cell profiles.
Breakup by Techniques:
- Molecular Approaches
- Image-Based Approaches
Molecular approaches represent the largest market share
Molecular approaches in cell analysis focus on studying cellular components at the molecular level to understand biological processes and diseases. Techniques include PCR (Polymerase Chain Reaction) for amplifying and detecting DNA or RNA sequences, Western blotting for protein detection and quantification, and next-generation sequencing (NGS) for comprehensive genomic analysis.
These methods enable researchers to investigate gene expression, mutations, protein interactions, and epigenetic modifications within cells. Molecular approaches are vital in biomarker discovery, drug development, and personalized medicine, offering insights into cellular function and disease mechanisms with high sensitivity and specificity. Continued advancements enhance their utility in diverse biomedical research applications.
Breakup by End-User:
- Pharmaceutical and Biotechnology Companies and CROs
- Hospitals and Diagnostic Laboratories
- Research Institutes
- Cell Culture Collection Repositories
- Others
Pharmaceutical and biotechnology companies and CROs currently account for the majority of the total market share
Pharmaceutical and biotechnology companies develop and commercialize drugs and therapies for medical use. They conduct extensive research and clinical trials to discover new compounds, validate their efficacy and safety, and obtain regulatory approvals. Contract Research Organizations (CROs) support these efforts by providing specialized, such as clinical trial management, data analysis, and regulatory compliance. CROs enable companies to outsource non-core activities, accelerate timelines, and manage costs effectively. Furthermore, the increasing rate of new drug development is also contributing to the segment’s growth. For instance, between 2010 and 2019, around 38 new drugs were approved each year, on an average.
That is about a 60% increase compared with the previous decade. Drug approvals reached a new peak in 2018, surpassing the record number of approvals of the late 1990s. The cell analysis market statistics by the publisher indicate that together, pharmaceutical/biotech firms and CROs are playing crucial roles in advancing healthcare innovation, bringing new treatments to market, and improving patient outcomes through rigorous scientific research and development.
Breakup by Region:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America currently dominates the global market
The growth of the region can be attributed to the increase in incidences of cancer and rising corporate and government funding in cell-based research. For instance, according to the Canadian Cancer Statistics 2022 Special Report, the number of people living with and after cancer in Canada continued to grow to over 1.5 million people. Additionally, according to another report, 2 in 5 Canadians are expected to be diagnosed with cancer in their lifetime. Approximately 1 in 4 Canadians is expected to die of the disease. Besides this, the presence of major companies, the growing number of product launches, and the strong R&D in biotechnology are further positively impacting the cell analysis market outlook.
For instance, in September 2022, Becton, Dickinson, and Company launched BD Research Cloud, a cloud-based software solution designed to streamline the flow cytometry workflow to enable higher-quality experiments with faster time to insight for scientists working across a range of disciplines, including immunology, virology, oncology, and infectious disease monitoring.
Competitive Landscape:
The competitive landscape of the industry has also been examined with the detailed profiles of the following key players:
- Agilent Technologies Inc.
- BD Biosciences
- Bio-RAD Laboratories Inc.
- Danaher Corporation
- Illumina Inc.
- Merck KGaA
- Miltenyi Biotec
- Olympus Corporation
- PerkinElmer Inc.
- Promega Corporation
- Sysmex Corporation
- Thermo Fisher Scientific
Global Cell Analysis Market News:
- June 2024: Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, announced the launch of the ddSEQ™ Single-Cell 3' RNA-Seq Kit and complementary Omnition v1.1 analysis software for single-cell transcriptome and gene expression research.
- March 2024: US-headquartered Cytek Biosciences, Inc., opened a new 50,000-square-foot facility in Wuxi, China. This strategic move increases the company's manufacturing capacity to meet the growing worldwide demand for comprehensive cell analysis solutions.
- February 2024: 10x Genomics, Inc., a leader in single-cell and spatial biology, announced the launch of GEM-X, the next generation of the company's leading single-cell technology. GEM-X is built on a new and improved microfluidic chip design, featuring the latest technological advancements and optimized reagents for superior performance and high reliability.
Key Questions Answered in This Report
1. What was the size of the global cell analysis market in 2023?2. What is the expected growth rate of the global cell analysis market during 2024-2032?
3. What are the key factors driving the global cell analysis market?
4. What has been the impact of COVID-19 on the global cell analysis market?
5. What is the breakup of the global cell analysis market based on the product?
6. What is the breakup of the global cell analysis market based on the analysis type?
7. What is the breakup of the global cell analysis market based on the techniques?
8. What is the breakup of the global cell analysis market based on the end-user?
9. What are the key regions in the global cell analysis market?
10. Who are the key players/companies in the global cell analysis market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis
2 Scope and Methodology
4 Introduction
5 Global Cell Analysis Market
6 Market Breakup by Product
7 Market Breakup by Analysis Type
8 Market Breakup by Techniques
9 Market Breakup by End-User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Agilent Technologies Inc.
- BD Biosciences
- Bio-RAD Laboratories Inc.
- Danaher Corporation
- Illumina Inc.
- Merck KGaA
- Miltenyi Biotec
- Olympus Corporation
- PerkinElmer Inc.
- Promega Corporation
- Sysmex Corporation
- Thermo Fisher Scientific
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 136 |
| Published | August 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 20.7 Billion |
| Forecasted Market Value ( USD | $ 40.1 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
